Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
1
Citations
NaN
KQI